Answers are grounded in this paper and cite their sources.
Pulmonary administration of inhalable nanoparticles (NPs) is an emerging area of interest. Dry powder inhalers may offer particular advantages for pulmonary administration of NPs. This article reviews research performed on the formulation of inhalable NPs as dry powder to achieve deep-lung deposition and enhance NP redispersibility. Moreover, the article summarizes up-to-date in vivo applications of inhalable NPs as dry powder inhalers.
No takes yet. Share an insight, caveat, or question.
Al-Hallak et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: